Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MVA-5T4
- Development stage
- Discontinued
- Lead developer
- Oxford BioMedica
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
MVA-5T4 (TroVax) is a therapeutic cancer vaccine based on the modified vaccinia Ankara (MVA) viral vector engineered to express the human tumor-associated antigen 5T4. The antigen 5T4 is an oncofetal glycoprotein highly expressed in a wide range of solid tumors—including renal cell carcinoma (RCC), colorectal cancer (CRC), prostate cancer, ovarian cancer, and mesothelioma—but rarely found in normal adult tissues. The primary mechanism involves stimulating both humoral and cellular immune responses against cells expressing the 5T4 antigen. Clinical trials have shown that vaccination with MVA-5T4 can induce robust anti-tumor immune responses and has been evaluated as monotherapy or in combination with agents such as cyclophosphamide or interleukin-2. Despite promising immunogenicity data and orphan drug designation for renal cell carcinoma, development for all major indications has been discontinued[1][2][3][6].
- Brand names
- TroVax
- Other names
- 5T4 cancer vaccineCancer vaccine - Oxford BiomedicaModified vaccinia Ankara 5T4MVA-h 5T4MVA-h5T4MVA-h-5T4Recombinant modified vaccinia Ankara 5T4 vaccine
02
Targets
TPBG (Trophoblast glycoprotein)
Beyond the preview
Go deeper on MVA-5T4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MVA-5T4.